SUMMARY
It was thought previously that non-depolarizing neuromuscular blocking agents in clinical doses did not cross the placenta [1] -a mistaken view caused probably by the absence of accurate assays for measurement of these drugs in low concentrations [2] . In 1968 it was suggested from a case report that this premise was incorrect [3] , and with the advent of improved analytical techniques it is now recognized that all non-depolarizing neuromuscular blocking agents, including tubocurarine [4] , pancuronium [5] , alcuronium [6] and vecuronium [7] cross the placenta to a degree determined by time and dose. Atracurium has been detected also in umbilical venous blood although, because of the limitations of the assay for this agent at that time, plasma concentrations of less than 50 ng ml" 1 could not be measured accurately [8] . In addition, umbilical concentrations of the metabolites of atracurium, including the potentially epileptogenic substance laudanosine, have not been reported. With the improved accuracy of detection of atracurium, laudanosine and another metabolite, monoquaternary alcohol (MQA), it is now possible to measure concentrations less than 10 ng ml" 1 [9, 10] . We have now studied maternal venous (MV), umbilical vein (UV) and umbilical artery (UA) plasma concentrations of these three substances during elective Caesarean section.
PATIENTS AND METHODS
Following approval by the local Ethics Committee, 22 healthy women undergoing elective Caesarean section under general anaesthesia were asked for their consent for plasma sampling of maternal venous and umbilical venous and arterial blood. All were in good health.
They received a standard anaesthetic in the supine position with a left lateral tilt. After an i.v. infusion was commenced and preoxygenation for 5 min, cricoid pressure was applied and anaesthesia induced with thiopentone 3-5 mg kg" 1 and suxamethonium 75-100 mg. The trachea was intubated and anaesthesia maintained with 50% nitrous oxide and 0.8% (inspired) enflurane in oxygen. End-tidal Pco 2 was monitored and maintained at 3-4 kPa. An i.v. cannula was inserted into the arm opposite to the i.v. infusion and 10 ml of blood obtained for measurement of control values. When there was evidence of recovery of neuromuscular function, atracurium 0.3 mg kg" 1 was given i.v. via the i.v. infusion and the time noted. The time of uterine incision and of delivery of the fetus were also recorded. Another sample of maternal blood (4 ml) was taken from the i.v. cannula immediately before delivery. A 15-20 cm length of doubly clamped umbilical cord was obtained immediately after delivery and samples of umbilical arterial and venous blood were obtained.
The neonate was assessed by the attending paediatrician and the Apgar scores at 1, 5 and 10 min were recorded. The time to onset of spontaneous regular ventilation was noted. The pH of the umbilical vein and arterial samples were measured using a IL BGM 1312 Blood Gas "Manager".
All the blood samples were acidified immediately, centrifuged and the plasma decanted into acidified test tubes before deep-freezing in liquid nitrogen and storage at -20 °C. The plasma was assayed for atracurium, laudanosine and MQA as described previously [9, 10] . The coefficient of variation of the assay for atracurium within the maternal blood range (100-2000 ng ml" 1 ) was 5 % and within the cord blood range (50-250 ng ml" 1 ) 7.5 %. Similarly, the coefficient of variation of the laudanosine assay within the maternal range (20-300 ng ml" 1 ) was 7.5 % and within the cord blood range (10-100 ng ml" 1 ) 6%. For MQA, the coefficient of variation was 8% for both maternal blood range (100-1000 ng ml" 1 ) and cord blood range (20-250 ng ml" 1 ). The lower limits of detection of the assay were 5 ng ml" 1 for atracurium, 2 ng ml" 1 for laudanosine and 10 ng ml" 1 for MQA. The ratios UV:MV, UA:MV and UA:UV were calculated for atracurium, laudanosine and MQA. UV: MV and UA: MV give an index of the degree of placental transfer, whilst the UA: UV ratio may be used to give an index of the extent of fetal equilibration of the three substances [11] . The three ratios for atracurium, laudanosine and MQA were plotted against time.
The relationship between the UV:MV, UA:MV and UA:UV ratios for atracurium, laudanosine and MQA and the time from administration of atracurium were analysed using Spearman's rank correlation coefficient. The significance of the resulting values was determined from standard tables [12] . P < 0.05 was considered significant.
RESULTS
The times from administration of atracurium to delivery of the fetus (range 1.25-18. The MV, UV and UA concentrations of atracurium, laudanosine and MQA are shown in table II, and the ratios UV:MV, UA:MV and UA: UV for atracurium, laudanosine and MQA in each patient are plotted against time from administration of atracurium to delivery of the fetus in figures 1-3. For all three substances, the three ratios of the two plasma concentrations correlated significantly with the time between administration of atracurium and delivery. The mean (SD) ratios in the 22 patients of UV: MV, UA:MV and UA:UV, for atracurium, laudanosine and MQA at delivery are given in table III.
DISCUSSION
Although water soluble, highly ionized drugs such as non-depolarizing neuromuscular blocking agents are not expected to cross lipid membranes such as the placenta, it is probable that the nonprotein bound fraction of these quaternary ammonium compounds gradually passes across this barrier [11] . The speed at which this occurs is thought to be related in part to the permeability of the placenta and the blood flow to it, both of which may be altered in disease states. It must be accepted, therefore, that significant patient variation is likely to occur in the degree of placental transmission of neuromuscular blocking agents, especially during emergency Caesarean section. For this reason, this study was limited to those patients undergoing elective Caesarean section who were not suffering from any disease states known to affect placental blood flow, such as diabetes mellitus or pre-eclampsia.
In the short time between induction and delivery, equilibration of atracurium, laudanosine and MQA would not be expected to have occurred between maternal venous and umbilical venous blood and this is confirmed by our results (tables II, III). The UV:MV ratios reported for other neuromuscular blocking drugs at delivery of the fetus vary between 11 % for vecuronium [7] , 12 % for tubocurarine [4] and 22% for pancuronium [5] . These data suggest that atracurium, with a mean ratio of 7%, may cross the placenta at a somewhat slower rate than the other nondepolarizing neuromuscular blocking agents, but generalizations are difficult because of the differences in time. The UV values in this study, in the range 44-189 ng ml" 1 , are broadly similar to those reported by Flynn, Frank and Hughes in 1984 [8] . It is not yet clear if UV, or UA, plasma concentrations are the more relevant when considering the potential effect of a neuromuscular blocking agent on the fetus. The umbilical arteries are branches of the common iliac arteries, which represent the continuation of the aorta. In the neonate, it is the descending aorta which supplies the majority of the somatic musculature. It would seem logical, therefore, to assume that it is the UA values which approximate more closely to those found at the neuromuscular junction. In our study, the mean (SD) UA value for atracurium was 55 (33.8) ng ml"
1 . Fisher and colleagues [13] demonstrated that the plasma atracurium concentration required to produce 50% neuromuscular block in infants aged 4-11 months was 363 (118) ng ml" 1 . Our results suggest that the doses of atracurium used routinely during Caesarean section are unlikely to result in significant neuromuscular block in the neonate.
Several factors affect the UV concentrations of the metabolites of atracurium. As both metabolites have a lower molecular weight than the parent compound, they cross the placenta more easily [11] . As laudanosine is, in addition, more lipid soluble than atracurium or MQA, of the three substances it might be expected to cross the placenta most rapidly. It is not surprising, therefore, that the UV: MV ratios were greater for the two metabolites than for the parent drug, with that of laudanosine being the greatest, at 19.4% (table III) . This may cause particular concern, as laudanosine is known to be epileptogenic in animals [14] . The concentration of laudanosine in the central nervous system, which is determined by the laudanosine concentration in the cerebral blood supply, is the important factor in this respect. In the fetus, the cerebral circulation receives a preferential supply of oxygenated blood returning via the UV. This flows via the inferior vena cava, through the foramen ovale, into the ascending aorta and thence to the carotid arteries. Thus, in contrast to the degree of neuromuscular block produced, the central nervous system laudanosine concentration may be determined more accurately by meauring the UV rather than the UA concentrations. In this study, the mean UV plasma concentration of laudanosine was 26 (13) ng ml" 1 . These values would not be expected to produce side effects in adult humans, and the maternal venous concentrations of less than 500 ng ml" 1 would not cause symptoms, the toxic values in dogs being more than 14000 ng ml" 1 [14] . It must be stressed, however, that the toxic concentration of laudanosine in the human neonate is unknown.
It is also interesting that, although the UV: MV ratios are greatest for the more lipid soluble laudanosine, the UA:UV ratios are smaller for this substance than for the more water soluble atracurium and MQA. It would be inappropriate to suggest that, in such a short time as 8 min, this smaller UA: UV ratio is caused by fetal excretion of laudanosine, even though it is recognized that the fetus may excrete drugs through the liver and kidney [11] and it is thought that laudanosine is excreted in part by these routes in adults [15, 16] . We feel that this finding may be explained only by the larger volume of distribution of the more lipid soluble laudanosine, which has already been demonstrated, although only in adults [9, 15] .
The mean UV:MV ratio of 10% for MQA is also in keeping with its molecular weight and known water solubility. Vandenbrom and colleagues [17] demonstrated recently that peak plasma MQA concentrations in healthy adults after a bolus dose of atracurium 0.5 mg kg" 1 were of the order of 1000 ng ml"
1 . The greatest MV value detected in this study after a smaller dose of atracurium was similar-HHngml" 1 . The greatest UV value, however was only 148 ng ml" 1 . No toxic effects of MQA have been documented yet and it is therefore unlikely that the concentrations detected in the fetal plasma in this study have any detrimental effect.
